Entrada Therapeutics, Inc.
General ticker "TRDA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $382.4M (TTM average)
Entrada Therapeutics, Inc. follows the US Stock Market performance with the rate: 24.7%.
Estimated limits based on current volatility of 3.7%: low 11.56$, high 12.45$
Factors to consider:
- Total employees count: 183 (+15.1%) as of 2024
- Top business risk factors: Operational and conduct risks, Limited operating history, Therapeutic candidate dependency, Early stage company risks, Market competition
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.72$, 16.09$]
- 2026-12-31 to 2027-12-31 estimated range: [6.92$, 14.66$]
Financial Metrics affecting the TRDA estimates:
- Negative: with PPE of -3.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -29.30 <= 0.01
- Positive: Investing cash flow per share per price, % of 26.64 > -0.63
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 81.12 > 64.29
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term TRDA quotes
Long-term TRDA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $129.01MM | $210.78MM | $25.42MM |
| Operating Expenses | $132.18MM | $163.77MM | $183.32MM |
| Operating Income | $-3.16MM | $47.01MM | $-157.90MM |
| Non-Operating Income | $15.22MM | $19.47MM | $15.07MM |
| R&D Expense | $99.88MM | $125.31MM | $142.27MM |
| Income(Loss) | $12.06MM | $66.48MM | $-142.83MM |
| Taxes | $18.74MM | $0.86MM | $0.92MM |
| Profit(Loss)* | $-6.68MM | $65.63MM | $-143.75MM |
| Stockholders Equity | $242.36MM | $428.68MM | $306.13MM |
| Assets | $469.19MM | $526.32MM | $377.38MM |
| Operating Cash Flow | $139.80MM | $-41.56MM | $-128.51MM |
| Capital expenditure | $5.61MM | $3.16MM | $1.04MM |
| Investing Cash Flow | $-138.40MM | $-27.80MM | $116.81MM |
| Financing Cash Flow | $21.04MM | $102.96MM | $0.89MM |
| Earnings Per Share** | $-0.20 | $1.76 | $-3.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.